Cambridge Healthtech Institute’s 9th Annual

Preclinical Strategies, Models & Tools in Oncology

Translational Strategies, Novel Therapeutics and Tumor Models 

June 2-4, 2020


The rise of cancer immunotherapy instigated unique preclinical and translational challenges. In addition to immuno-oncology advances, we are witnessing a new wave of targeted and novel therapies that enrich the arsenal of combination cancer therapies. The demand for predictive and robust preclinical models and approaches to minimize translational failures in oncology and immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions adds to the complexity of translational research in oncology and immuno-oncology. Cambridge Healthtech Institute’s 9th Annual Preclinical Strategies, Models & Tools in Oncology conference is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

TRANSLATIONAL ONCOLOGY AND IMMUNO-ONCOLOGY

Leveraging Multi-Targeting for More Effective Cancer Immunotherapy
Dmitri Wiederschain, PhD, Global Head, Immuno-Oncology Research Therapeutic Area, Sanofi

External R&N in Immuno-Oncology
Michael Woo, PhD, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

NOVEL THERAPEUTICS AND TECHNOLOGIES

CD3 Bispecific Platform
Divya Mathur, PhD, Associate Research Fellow, Targeted Immunotherapy, Pfizer-Oncology

Bispecific T Cell Engagers: Overview of Amgen‘s BiTE® Pipeline
Benno Rattel, PhD, Executive Director Research Amgen, CBSS, Amgen

Immunoregulatory Roles Exerted by Specific Subsets of Mesenchymal Cells in The Tumor Microenvironment
Viviana Cremasco, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis

Preclinical and Translational Imaging Methods in the Development of Immuno-Oncology Therapeutics
Charles Glaus, PhD, Scientific Director, Quantitative & Translational Science, Imaging, Takeda Pharmaceuticals

Friends & Enemies: Spatial Mapping of Regulatory T Lymphocytes in Inflammatory Microenvironments
Shawn O’Neill, DVM, PhD, Senior Director, Global Pathology & Investigative Toxicology, Global Microscopic Imaging Lead, Drug Safety Research & Development, Pfizer Worldwide Research & Development

TUMOR MODELS

Preclinical Modeling Using Human Cancer Xenografts Grown in Immune-Deficient Zebrafish
David Langenau, PhD, Associate Chief of Research and Director of Molecular Pathology, Massachusetts General Hospital; Associate Professor, Pathology, Harvard Medical School

Humanized Mouse Models Update
Brandon Antonakos, PhD, Scientist II, Oncology Pharmacology at Novartis Institutes for BioMedical Research

Development and Characterization of a Novel Syngeneic Melanoma Model
Viswanathan Muthusamy, PhD, Research Scientist; Executive Director, Center for Precision Cancer Modeling, Yale School of Medicine